Skip to main content

FDA Issued MRI Safety Guidance For Medical Devices

FDA Issued MRI Safety Guidance For Medical Devices

FDA Issued MRI Safety Guidance For Medical Devices

Introduction

The FDA issued new federal draft guidance on August 2, 2019, titled “Testing and Labeling Medical Devices for Safety in the Magnetic Resonance Environment,” providing an outline about medical devices such as pacemakers, neurostimulators, insulin pumps, artificial heart valves, and cochlear implants that are meant to undergo Magnetic Resonance (MR) environment. The new guidance would supersede the FDA’s 2014 recommendations.

Many medical devices and implants cannot enter a Magnetic Resonance Imaging (MRI) machine as they are metallic and can cause abnormalities to the images or harm the patient. However, manufacturers have started designing MRI compatible medical devices. Pacemakers implanted in 2018 were 70% MRI-compatible as compared to 12% compatibility in 2016.

The guidance explains how to determine the medical devices and implants that are safe to enter a magnetic resonance imaging (MRI) machine, whose exposure to powerful magnetic fields could dangerously affect the patient's body. The guidance states that the devices should also include safety labeling, indicating the device is “MR Safe,” “MR Unsafe,” or “MR Conditional,” according to its compatibility with the MR environment or have special guidance for use in the MRI machine.

The details on how to undertake testing to evaluate the safety and compatibility of medical devices in the MR environment along with a format of MRI was also mentioned in the guidance.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!